natgillin/translations-raw huggingface dataset:
combining the feed water of step a) and the aqueous slurry of step b) in order to obtain remineralized water, wherein the concentration of calcium carbonate in the slurry is from 2 to 40 wt.-%, based on the total weight of the slurry. 
miješanje pojne vode iz koraka a) i vodene guste otopine iz koraka b) kako bi se dobila remineralizirana voda, naznačen time da koncentracija kalcijevog karbonata u gustoj otopini je od 2 do 40 tež.-%, u odnosu na ukupnu masu guste otopine.
The anti-human TSLP receptor antibody according to claim 1, comprising the heavy chain consisting of the amino acid sequence shown by SEQ ID NO: 1 and the light chain consisting of the amino acid sequence shown by SEQ ID NO: 3. 
Protutijelo protiv ljudskog receptora TSLP u skladu s patentnim zahtjevom 1, naznačeno time što sadrži teški lanac koji se sastoji od aminokiselinskog slijeda kojeg prikazuje SEQ ID NO: 1 i laki lanac koji se sastoji od aminokiselinskog slijeda kojeg prikazuje SEQ ID NO: 3.
The use according to Claim 6, wherein the viral infection is caused by a virus selected from the group consisting of dengue virus, yellow fever virus, West Nile virus, Japanese encephalitis virus, tick-borne encephalitis virus, Kunjin virus, Murray Valley encephalitis virus, St. Louis encephalitis virus, Omsk hemorrhagic fever virus, bovine viral diarrhea virus, Zika virus and Hepatitis C virus. 
Spoj za uporabu prema patentnom zahtjevu 23 gdje je virusna infekcija uzrokovana virusom iz skupine koju čine denga virus, virus žute groznice, virus Zapadnog Nila, virus japanskog encefalitisa, virus krpeljnog meningoencefalitisa, Kunjin virus, virus encefalitisa Doline Marej, virus encefalitisa Sent Luis, virus Omsk hemoragične groznice, virus Bovina virusne dijareje, Zika virus i virus hepatitisa C.
W is a group of formula (Wc) wherein 
W je skupina formule (WC) E 2
The composition of claim 13, for the use of claim 13, wherein said whole organ is a member selected from kidney, heart, liver, intestine, pancreas and lung. 
Pripravak u skladu s patentnim zahtjevom 13, namijenjen upotrebi u skladu s patentnim zahtjevom 13, naznačen time što je navedeni cijeli organ član kojeg se bira između bubrega, srca, jetre, crijeva, gušterače i pluća.
It should of course be understood that an important feature of such particles is the actual crystal size in that the crystal size (and not the particle size) will be determinative for the preferred crystal phase under given conditions (see also further below). 
Naravno, valja razumjeti da je važna karakteristika takvih čestica prava veličina kristala jer će veličini kristala (a ne veličina čestica) biti odrednica za preferiranu veličinu kristalne faze pod danim uvjetima (vidi također dalje niže).
A process for synthesizing nebivolol wherein the preparation of a compound of formula 
Postupak sinteze nebivolola naznačen time što priprema spoja formule
The intermediate 1,4,5,6-Tetrahydro-cyclopentapyrazole-3-carbonitrile was prepared using the following procedure. 
Intermedijerni 1,4,5,6-Tetrahidro-ciklopentapirazol-3-karbonitril je pripremljen uporabom slijedećeg postupka:
The solvent is removed in vacuo and the crude is triturated with diethyl ether, DCM and ethyl acetate. 
Otapalo se odstrani u vakuumu i sirov proizvod se triturira s dietil eterom, DCM-om i etil acetatom.
the second binding domain is capable of binding to the T cell CD3 receptor complex; and wherein epitope cluster 3 of BCMA corresponds to amino acid residues 24 to 41 of the sequence as depicted in SEQ ID NO: 1002, and epitope cluster 4 of BCMA corresponds to amino acid residues 42 to 54 of the sequence as depicted in SEQ ID NO: 1002. 
(b) druga vezujuća domena sposobna je za vezanje na CD3; i pri čemu epitop klastera 3 od BCMA odgovara ostatcima aminokiseline 24 do 41 od sekvence kao što je prikazano u SEQ ID NO: 1002, i pri čemu je navedena vezujuća molekula polipeptid.
An IL-17 antibody for use in treating ankylosing spondylitis (AS) or psoriatic arthritis (PsA), characterized in that the IL-17 antibody is to be: 
Secukinumab za uporabu u liječenju ankilozantnog spondilitisa (AS), naznačen time, što secukinumab treba:
The crystalline Form A of N -methyl-1-{trans -4-[methyl(7 H -pyrrolo[2,3- d]pyrimidin-4-yl)amino]cyclohexyl}methanesulfonamide maleic acid salt according to claim 4, which comprises an X-ray powder diffraction pattern having at least one characteristic peak expressed in degrees 2-theta at approximately 6.2, 12,6 and 15.7. 
Kristalni Oblik A soli N-metil-1-{trans-4-[metil(7H-pirolo[2,3-d]pirimidin-4-il)amino]cikloheksil}metansulfonamida s maleinskom kiselinom u skladu s patentnim zahtjevom 4, naznačen time što njegov uzorak difrakcije rendgenskih zraka na prahu ima najmanje jedan karakteristični signal, izražen u stupnjevima 2θ, na otprilike 6,2, 12,6 i 15,7.
The minimally invasive skin treatment device of Claim 1, wherein the tool comprises: a cutting blade (303); and a reciprocating motor (404) coupled to the cutting blade, said reciprocating motor reciprocating the cutting blade. 
Uređaj za minimalno invazivni tretman kože u skladu s patentnim zahtjevom 1, naznačen time, da alat ima: oštricu za rezanje (303) i izmjenični motor (404) spojen na nož za rezanje, navedeni izmjenični motor rTecipročno pokreće oštricu za rezanje.
The 1,1,1,2,3-pentachloropropane product is removed from the reaction zone in a liquid effluent and subsequently introduced into a second reaction zone shown in the lower portion of Figure 3 . 
Postupak prema zahtjevu 16, gdje se sirovi tekući proizvod 1,1,1,2,3-pentakloropropana iz koraka (iii) izravno puni bez pročišćavanja u reakcijsku zonu u koraku (iv).
The dark-yellow precipitate that formed was filtered and washed three times with water and allowed to air dry. 
Nastali tamnožuti precipitat se filtrira i opere tri puta s vodom i pusti sušiti na zraku, Dobiva se 2,6 g narančasto-žutog produkta 3, t. t.
transporting the pre-fuel composition comprising methanol and dimethyl ether from a first location to a second location remote from the first location. 
- < transport smjese predgoriva koja sadrži metanol i dimetil eter s prve lokacije na drugu lokacije udaljenu od prve lokacije.
A method for the treatment of agitation or a symptom thereof in an individual in need thereof suffering from dementia comprising administering to the individual a therapeutically effective amount of a pharmaceutical composition comprising Form II of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and an excipient selected from the group consisting of PVP and coPVP. 
Oblik I 1-[3-(4-bromo-2-metil-2H-pirazol-3-il)-4-metoksi-fenil]-3-(2,4-difluoro-fenil)-uree u količini od oko 0.01 % do oko 5 masenih % cjelokupnog pripravka, pri čemu navedeni Oblik I je kristalni oblik koji ima uzorak rendgenske difrakcije praha koji obuhvaća vrške, u pogledu 2θ, kod oko 5.6 °, oko 7.4 °, oko 11.2 °, oko 21.1 ° i oko 25.0 °;
The pharmaceutical composition for topical use according to claims 2-5 in the form of an ointment, lipogel, hydrogel, lipstick, cream, patches, foam, mucosal gel, ophthalmic preparations, mouthwash, solutions for topical application. 
Farmaceutski pripravak za upotrebu prema patentnim zahtjevima 3 - 6, koji je u obliku masti, lipogela, hidrogela, ruža, kreme, flastera, vaginalnih ovula i čepića, pjene, gela za sluznicu, oftalmoloških pripravaka, vaginalnih tekućina, tekućine za ispiranje usta, otopina za topikalnu primjenu ili inhalaciju.
The glatiramer acetate and the rasagiline for use according to claim 34, wherein the glatiramer acetate and the rasagiline are administered separately. 
Glatiramer acetat i rasagilin za uporabu u skladu s patentnim zahtjevom 34, naznačeni time, da se glatiramer acetat i rasagilin daju odvojeno.
For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. 
U tu svrhu može se upotrijebiti koncentrirane šećerne otopine, koji izborno mogu sadržavati arapsku gumu, talk, polivinilpirolidon, karbopolni gel, polietilen-glikol i(li) titanijev dioksid, otopine za lakiranje, te pogodna organska otapala ili smjese otapala.
Use of high molecular weight polyethylene oxide that has, based on rheological measurements, a molecular weight of at least 800,000, as matrix forming material in the manufacture of a solid extended release oral dosage form comprising an active agent selected from opioids for imparting to the solid extended release oral dosage form resistance to alcohol extraction. 
Upotreba polietilen oksida visoke molekulske težine koji ima, bazirano na reološkim mjerenjima, molekulsku težinu od barem 1,000,000, kao materijal koji formira matricu u proizvodnji oralnog oblika za doziranje s produljenim otpuštanjem u krutom obliku koji sadrži aktivni agens odabran iz opioida za davanje oralnom obliku za doziranje s produljenim otpuštanjem u krutom obliku otpornost na ekstrakciju alkoholom.
Rats received a single oral dose of 100 mg/Kg of the compounds. 
Å takori su primili jednostruku oralnu dozu od 100 mg/Kg spojeva.
The formulation of claim 1, wherein the second polymeric material is a blend of at least two different polymers having a pH threshold of about pH 5 and above. 
Formulacija lijeka s odloženim otpuštanjem sukladno u jednom od prethodnih patentnih zahtjeva, naznačeno time, da je drugi polimerni materijal spoj najmanje dva različita polimera koji imaju prag na pH od pH 6 ili više.
The derivative according to claim 5, selected from the group consisting of OA-SEQ ID NO. 
Derivat u skladu s patentnim zahtjevom 5, odabran iz grupe koja se sastoji od OA-SEQ ID NO.
the heavy chain complementarity determining region HCDR1 includes the amino acid sequence of SEQ ID NO: 2255, the HCDR2 includes the amino acid sequence of SEQ ID NO: 2256 and the HCDR3 includes the amino acid sequence of SEQ ID NO: 2257, and the light chain complementarity determining region LCDR1 includes the amino acid sequence of SEQ ID NO: 2258, the LCDR2 includes the amino acid sequence of SEQ ID NO: 2259 and the LCDR3 includes the amino acid sequence of SEQ ID NO: 2260; 
HCDR1 regije za određivanje komplementarnosti teškog lanca koji sadrži aminokiselinsku sekvencu od SEK ID BR: 2255, HCDR2 koji sadrži aminokiselinsku sekvencu od SEK ID BR: 2256 i HCDR3 koji sadrži aminokiselinsku sekvencu od SEK ID BR: 2257 i LCDR1 regije za određivanje komplementarnosti lakog lanca koji sadrži aminokiselinsku sekvencu od SEK ID BR: 2258, LCDR2 koji sadrži aminokiselinsku sekvencu od SEK ID BR: 2259 i LCDR3 koji sadrži aminokiselinsku sekvencu od SEK ID BR: 2260; i
Collecting water with a concentration of total dissolved solids (TDS) of up to 50,000 ppm; 
skupljanje vode koja ima koncentraciju ukupnih otopljenih čvrstih čestica (TDS) do 50 000 ppm;
The receiver of claim 9 or 10, wherein the first FEC decoder comprises: a de-puncturing means configured to perform de-puncturing on LDPC parity bits; an LDPC decoder configured to LDPC-decode the L1 signaling data and the de-punctured LDPC parity bits; and 
Prijamnik iz patentnog zahtjeva 7, pri čemu prvi FEC dekoder obuhvaća: sredstvo zatvaranja probijanja konfigurirano za zatvaranje probijanja na LDPC paritetnim bitovima;
Typically the housing would include three distance markings (although other numbers of markings are possible), corresponding to per se known FINNEGAN “low”, “medium” and “high” levels of pre-load. 
Uobičajeno je da kućište ima tri oznake za razmak (i uz to što je moguć i drugi broj oznaka) koje odgovaraju unaprijed "o" oznatim razinama predopterećenja "niza
A product comprising (a) a B2 agonist as defined in any one of claims 1 and 3 to 7 and (b) an antagonist of M3 muscarinic receptors as defined in claim 1 or 2, as a combined preparation for simultaneous, concurrent, separate or sequential use in the treatment of a patient suffering from or susceptible to a respiratory disease as defined in claim 11 or 12, while producing less heart side-effects than a therapeutically equivalent combination of tiotropium with the B2 agonist. 
Proizvod koji sadrži (a) P2 agonist kako je definiran u bilo kojem od patentnih zahtjeva 1 i 3 do 7 i (b) antagonist M3 muskarinskih receptora kako je definiran u patentnom zahtjevu 1 ili 2, naznačen time, da je to proizvod u obliku kombiniranog pripravka za istovremenu, paralelnu, odvojenu ili sekvencijalnu uporabu u liječenju bolesnika koji su oboljeli ili bi mogli oboljeti od bolesti dišnih putova koje su definirane u patentnom zahtjevu 11 ili 12.
A source of elastic vibrations is installed on the surface of the wellhead of the oil producing well. 
Izvor elastičnih vibracija je postavljen na površinu naftnog izvora iz kojeg se proizvodi nafta.
A first outer part 10 is attached to the side 4 and a second outer part 12 is attached to the side 6. 
Prvi vanjski dio 10 je pričvršćen na stranu 4, a drugi HR P20060319 T3 vanjski dio 12 je pričvršćen na stranu 6.
is hydrogen, lower alkyl optionally substituted by substituent group A, lower alkenyl optionally substituted by substituent group A, lower alkynyl optionally substituted by substituent group A, carbocyclic group optionally substituted by substituent group A, carbocycle lower alkyl optionally substituted by substituent group A, carbocycleoxy lower alkyl optionally substituted by substituent group A, heterocycle lower alkyl optionally substituted by substituent group A, —Z—N(RZ1)—SO2—RZ2, 
R> je vodik, niži alkil prema potrebi supstituiran sa supstituentskom skupinom A, niži alkenil prema potrebi supstituiran sa supstituentskom skupinom A, niži alkinil prema potrebi supstituiran sa supstituentskom skupinom A, karbociklička skupina prema potrebi supstituirana sa supstituentskom skupinom A, karbociklički niži alkil prema potrebi supstituiran sa supstituentskom skupinom A, karbocikloksi niži alkil prema potrebi supstituiran sa supstituentskom skupinom A, heterociklički niži alkil prema potrebi supstituiran sa supstituentskom skupinom A,
These compositions are suitable for pharmaceutical use, as shown by the PROLEUKIN™ product. 
Ovi sastavi su prikladni za farmaceutsku uporabu, kako je prikazano proizvodom PROLEUKINTM,
preparing a solution of 1-cyano-2-(4-cydopropyl-benzyl)-4-(B-D-glucopyranos-1-yl)-benzene and the one or more natural amino acids in a solvent or a mixture of solvents; 
(a) pripravljanje otopine od 1-cijano-2-(4-ciklopropil-benzil)-4-(B-D-glukopiranoz-1-il)-benzena i jedne ili više prirodnih aminokiselina u jednom otapalu ili u mješavini otapala;
The sliding door system of any of claims 3 - 4, wherein the opening exposed is sized to receive a battery for the vehicle there through. 
Sustav kliznih vrata prema zahtjevu 3, pri čemu je nastali otvor (620) veličine kroz koju se može uzeti baterija (104) iz vozila.
A compound of Formula (I), according to claim 1 selected from the following group: 
Spoj s formulom (1), prema zahtjevu 1 naznačen time da je odabran 1z slijedeće skupine:
exchanging heat between the LNG and the boil-off gas before supplying the LNG to the high-pressure gas injection engine. 
uplinjavanje stlačenog LNG; te dobavljanje uplinjenog LNG u visokotlačni plinski injekcijski motor.
In the examples below it is demonstrated that by loading the crude material at lower pH, an increase in IL-18BP capacity of about two-fold and higher was obtained. 
U donjim je primjerima pokazano da se nanošenjem sirovog materijala pri nižem pH postiže kapacitet IL-18BP dvaput ili više.
amino acids having a sequence at least 80% identical to a light chain variable domain sequence of L5; 
aminokiseline koje imaju slijed najmanje 80% identičan slijedu SEQ ID NO:363; di.
for the manufacture of a medicament packed in a container with an outlet valve for use in the treatment of psoriasis or for the prophylaxis thereof or for the manufacture of a cosmetic product packed in a container with an outlet valve. 
8.50 g Mješavinu pogonskog sredstva naznačena time da je za proizvodnju lijeka pakiranog u spremnik s ispusnim ventilom za liječenje rosacea ili akni.
ii) According to a preferred embodiment of this invention, the compounds of formula I as defined in embodiment i) above, or their pharmaceutically acceptable salts, will be such that R1 represents methoxy or ethoxy (and preferably methoxy). 
Uporaba prema zahtjevu 1, naznačena time, da je spoj formule la ili njegova farmaceutski prihvatljiva sol takav/takva da R! predstavlja metoksi ili etoksi.
In some embodiments, compounds of the present invention are of Formula (Iv) wherein X is NH. 
U nekim oblicima, spojevi prema izumu su Formule (Iv) gdje X je NH.
In the moiety represented by Z, R4 represents an aromatic hydrocarbon group which is optionally substituted or an unsaturated heterocyclic group which is optionally substituted. 
R* predstavlja aromatsku ugljikovodičnu skupinu koja je po izboru supstituirana ili nezasićenu heterocikličku skupinu koja je po izboru supstituirana, izuzev spoja uracila predstavljenog općom formulom (1), pri čemu je
A cancer chemotherapeutic agent according to any of claims 1 to 4, which is in the form of a kit including a drug containing a cholestanol derivative and a drug containing an anti-cancer agent. 
Protutumorsko kemoterapijsko sredstvo u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačeno time, da je u obliku kompleta koji uključuje lijek koji sadrži derivate kolestanola 1 lijek koji sadrži protutumorsko sredstvo.
The composition or vaccine of claim 5, wherein the expression of the first heterologous polynucleotide coding for and expressing an NDV-F antigen is regulated by the SV40 promoter having the sequence as set forth in SEQ ID NO: 9. 
NDV-F-gen koji ima polinukleotidnu sekvencu prikazanu u SEQ ID BR:1, koji je operativno povezan s SV40 promotorom i SV40 poliA-signalom, i umetnut je u IG1 lokus od HVT genoma; ili
leaving the solution to act at a temperature from room temperature up to the boiling temperature of the solution, and 
ostavljanje otopine da djeluje na temperaturi od sobne temperature do temperature ključanja otopine, ispiranje.
comprising reacting a compound of formula (XVI-S), wherein Q2 is bromo, chloro or iodo, with a magnesium reagent; in an organic solvent; to yield the corresponding compound of formula (XVII-S), wherein Q3 is the corresponding Grignard species; 
(XVILS) reagiranje spoja formule (XVI-S), gdje je Q* bromo, kloro ili jodo, sa magnezijevim reagensom; u organskom otapalu; kako bi se dobio odgovarajući spoj formule (XCVII-S), gdje je Q* odgovarajuća Gringard-ova vrsta;
The antibody of 1, wherein the heavy chain comprises a variable region and a constant region, wherein the variable region comprises an amino acid sequence as set forth in SEQ ID NO: 10, or an antigen-binding or immunogenic fragment thereof. 
Antitijelo ili antigen vezujući fragment istog prema zahtjevu 1, naznačen time da teški lanac obuhvaća varijabilnu Tegiju i konstantnu regiju, naznačen time da varijabilna regija ima slijed SEQ ID NO: 10.
a second promoter operably linked to a nucleic acid encoding an immunogenic heterologous polypeptide for use in a method of treatment eliciting an immune response, said method comprising administering an immunogenically effective amount of the vector to a mammalian subject such as a human, wherein the immune response is directed against the heterologous polypeptide, and wherein the route of administration is selected from the group consisting of oral, intranasal, and mucosal such as vaginal. 
(b) drugog promotora operativno povezanog s nukleinskom kiselinom koja kodira imunogeni heterologni polipeptid za primjenu u postupku liječenja koji izaziva imunološki odgovor, pri čemu se spomenuti postupak sastoji od primjene imunogeno učinkovite količine vektora na sisara, npr. čovjeka, naznačen time, što je imunološki odgovor usmjeren protiv heterolognog polipeptida i naznačen time, što je put primjene odabran iz grupe koja se sastoji od oralne primjene, intranazalne primjene i mukozne primjene npr. vaginalne.
in the shape of taps/barbs and recesses/collars as indicated in the Figures or any other kind of snap mechanism. 
u obliku nastavka/kvačica i udubljenja/prstena, kako je bilo prikazano na slikama, ili bilo koji uskočni mehanizam drugačije vrste.
The use of a separate container offers the best guarantee in this respect. 
S obzirom na to, korištenje odvojenog spremnika pruža najbolju garanciju.
The mixture was stirred at room temperature for 16 hours, diluted with ethanol (150 ml), and the pH adjusted to 6-7 with 4M hydrochloric acid. 
Smjesa se miješa na sobnoj temperaturi 16 sati, razblaži se etanolom (150 ml) i pH se podesi na 6-7 s 4M, klorovodičnom kiselinom.
reacting the compound of the above formula IIIa with an organoborane compound of formula 
Of e c) reakciju spoja gore navedene formule IIla s organoboranskim-spojem formule, ka
The antibody drug conjugate for use according to any one of claims 1-24, wherein the anti-DLL3 antibody comprises residues 30-36 of SEQ ID NO: 84 for CDR-L1, residues 46-55 of SEQ ID NO: 84 for CDR-L2, residues 89-96 of SEQ ID NO: 84 for CDR-L3, residues 30-35 of SEQ ID NO: 85 for CDR-H1, residues 47-58 of SEQ ID NO: 85 for CDR-H2 and residues 93-101 of SEQ ID NO: 85 for CDR-H3, wherein the residues are numbered according to MacCallum. 
Konjugat protutijelo-lijek prema bilo kojem od zahtjeva 1 do 5, 12 ili 13, naznačen time, da protutijelo anti-DLL3 obuhvaća ostatke od 30 do 36 od SEQ ID NO:84 za CDR-LI, ostatke od 46 do 55 od SEQ ID NO:84 za CDR-L2, ostatke od 89 do 96 od SEQ ID NO:84 za CDR-L3, ostatke od 30 do 35 od SEQ ID NO:85 za CDR-HI, ostatke od 47 do 58 od SEQ ID NO:85 za CDR-H2 i ostatke od 93 do 101 od SEQ ID NO:85 za CDR-H3, pri čemu su ostatci HR P20171549 T1 numerirani prema sustavu MacCallum.
The C1-C8-alkyl groups in di(C1-C8-alkyl)amino may be the same or different. 
C,-Cg-alkilne skupine u di(C;-Cg-alkiljamino mogu biti iste ili različite.
The composite structure according to any preceding claim wherein the fiber containing layer comprises at least one of the group consisting of bleached Kraft board, unbleached Kraft board, recycled folding boxboard, folding box board, coated recycled board, and uncoated recycled board. 
Kompozitna struktura sukladno bilo kojem od prethodnih zahtjeva, naznačen time, što sloj koji sadrži vlakna i koji sadrži najmanje barem jednu skupinu koja se sastoji od izbjeljene ili neizbjeljene šper ploče, recikliranog sklopivog kartona, savitljivog kartona, premazanog savitljivog kartona i nepremazanog recikliranog kartona.
The PET container of claim 3 wherein the container is optically clear. 
PET posuda iz patentnog zahtjeva 1 ili 5 gdje je posuda optički prozirna.
The drying was stopped and the substance was exposed to humid air (relative humidity under 60 %) to achieve an assay of water of 4.14 % (Karl Fischer). 
Sušenje je bilo zaustavljeno, a dobivena tvar je bila izložena vlažnom zraku (relativna vlažnost ispod 60 %) čime je postignut esej vode od 4,14 % (određeno Karl Fischerovom metodom).
In another preferential variant, this method is characterised in that when the fractions are obtained in step d) the average particle sizes of the said fractions have a ratio of 1:1.05 to 1:150, and preferentially 1:1.1 to 1:1.15. 
Postupak prema zahtjevu 1, naznačen time da kada su frakcije dobivene u koraku d) prosječne veličine čestica navedenih frakcija imaju omjer od 1:1.05 do 1:150, te poželjno 1:1.1 do 1:1.15.
International Publication WO 2007/036709 
Datum međunarodne objave:
with a reagent capable of causing a protecting group to be attached to the phenolic oxygen of a compound of Formula 6 in the presence of a solvent, thereby producing a compound of Formula 7 
R2 Formula 6 s reagensom koji može uzrokovati da se zaštitna skupina veže za fenolni kisik spoja koji s formulom 6 u prisutnosti otapala.